Incidence and demography of femur fractures with and without atypical features

Journal of Bone and Mineral Research

Volumn 27, Issue 5, 2012, Pages 977-986

  Feldstein, Adrianne C ^a,b   Black, Dennis ^c   Perrin, Nancy ^a   Rosales, A Gabriela ^a   Friess, Darin ^d   Boardman, David ^b   Dell, Richard ^b   Santora, Arthur ^e   Chandler, Julie M ^e   Rix, Mary M ^a   Orwoll, Eric ^d  

^a CENTER FOR HEALTH RESEARCH   (United States)

^b KAISER PERMANENTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

ATYPICAL FRACTURE; BISPHOSPHONATE; SUBTROCHANTERIC AND FEMORAL SHAFT FRACTURES

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; GLUCOCORTICOID;

ADULT; AGED; ARTICLE; BONE RADIOGRAPHY; CROSS-SECTIONAL STUDY; ELECTRONIC MEDICAL RECORD; FEMALE; FEMUR FRACTURE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; RISK FACTOR; STRESS FRACTURE;

AGED; DIPHOSPHONATES; FEMALE; FEMORAL FRACTURES; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES;

EID: 84859432670     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1550     Document Type: Article

References (21)

1. Cummings SR, Kelsey JL, Nevitt MC, O'Dowd KJ., Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev. 1985; 7: 178-208.
2. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A., Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007 Mar; 22 (3): 465-75.
3. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996 Dec 7; 348 (9041): 1535-41.
4. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C., Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev. 2002 Aug; 23 (4): 570-8.
5. Boonen S, Laan RF, Barton IP, Watts NB., Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int. 2005 Oct; 16 (10): 1291-8.
6. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007 Nov 1; 357 (18): 1799-809.
7. Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res. 2004 Aug; 19 (8): 1259-69.
8. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG., Low-energy femoral shaft fractures associated with alendronate use. J OrthopTrauma. 2008 May; 22 (5): 346-50.
9. Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, Howe TS., Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br. 2007 Mar; 89 (3): 349-53.
10. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS., An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?. Injury. 2008 Feb; 39 (2): 224-31.
11. Lenart BA, Lorich DG, Lane JM., Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med. 2008 Mar; 358 (12): 1304-6.
12. Giusti A, Hamdy NA, Papapoulos SE., Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone. 2010 Aug; 47 (2): 169-80.
13. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C., The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 2004 Dec; 15 (12): 1003-8.
14. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010 Nov; 25 (11): 2267-94.
15. Huybrechts KF, Ishak KJ, Caro JJ., Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone. 2006 Jun; 38 (6): 922-8.
16. Weycker D, Macarios D, Edelsberg J, Oster G., Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int. 2007 Mar; 18 (3): 271-7.
17. Abrahamsen B, Eiken P, Eastell R., Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res. 2009 Jun; 24 (6): 1095-102.
18. Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunraj N, Austin PC, Whelan DB, Weiler PJ, Laupacis A., Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA. 2011 Feb 23; 305 (8): 783-9.
19. Schilcher J, Michaelsson K, Aspenberg P., Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med. 2011 May 5; 364 (18): 1728-37.
20. Giusti A, Hamdy NA, Dekkers OM, Ramautar SR, Dijkstra S, Papapoulos SE., Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. Bone. 2011 May 1; 48 (5): 966-71.
21. Feldstein AC, Vollmer WM, Smith DH, Petrik A, Schneider J, Glauber H, Herson M., An outreach program improved osteoporosis management after a fracture. J Am Geriatr Soc. 2007; 55 (9): 1464-9.